A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes.
John M Wentworth, Spiros Fourlanos, Peter G Colman, Leonard C Harrison
Metabol Open | Published : 2020
Introduction: Sodium-glucose linked transporter (SGLT) inhibitors could improve glycaemia and simplify insulin regimens in recent-onset type 1 diabetes (T1D), provided they were well-tolerated and safe. This study aimed to determine the feasibility and safety of a SGLT inhibitor for the treatment of recent-onset T1D. Method: An open label, prospective pilot study in adults with recent-onset T1D was performed. Empagliflozin, 25 mg orally daily, was given in combination with insulin and multidisciplinary care during a 24-week treatment phase, followed by wash-out visits at weeks 30 and 36. Results: Fourteen participants (4 women; median age 26 years) began and 13 completed the study. No treatm..View full abstract